GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+10.61%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$484M
AUM Growth
+$484M
(+16%)
Cap. Flow
+$82.3M
Cap. Flow
% of AUM
17.02%
Top 10 Holdings %
Top 10 Hldgs %
51.89%
Holding
57
New
15
Increased
16
Reduced
7
Closed
15
Top Buys
| 1 |
RAPT Therapeutics
RAPT
|
$22.2M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$17.7M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$15.9M |
| 4 |
OPTN
OptiNose
OPTN
|
$14.6M |
| 5 |
Viking Therapeutics
VKTX
|
$12.2M |
Top Sells
| 1 |
Relmada Therapeutics
RLMD
|
$18.9M |
| 2 |
Galapagos
GLPG
|
$13.1M |
| 3 |
Alkermes
ALKS
|
$12.1M |
| 4 |
BridgeBio Pharma
BBIO
|
$10.4M |
| 5 |
Travere Therapeutics
TVTX
|
$10.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Replimune Group
REPL
$422M
| – | – | -390,000 | Closed | -$6.74M |
|
|
52
Relmada Therapeutics
RLMD
$37.2M
| – | – | -510,000 | Closed | -$18.9M |
|
|
SLN
53
Silence Therapeutics
SLN
$227M
| – | – | -68,915 | Closed | -$692K |
|
54
Spyre Therapeutics
SYRE
$996M
| – | – | -2,500,000 | Closed | -$1.32M |
|
|
PVLA
55
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| – | – | -1,965,449 | Closed | -$2.26M |
|
|
NGM
56
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| – | – | -316,256 | Closed | -$4.14M |
|
|
TCDA
57
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – | -870,000 | Closed | -$9.12M |
|